SG/CALL/MEDTRONIC/100/0.1/20.06.25 Stock

Warrant

DE000SU2YLL3

Market Closed - Boerse Frankfurt Warrants 15:41:14 2024-07-05 EDT
0.13 EUR +8.33% Intraday chart for SG/CALL/MEDTRONIC/100/0.1/20.06.25
3 months-66.67%
6 months-73.47%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-07-05 0.13 +8.33%
24-07-04 0.12 0.00%
24-07-03 0.12 0.00%
24-07-02 0.12 +9.09%
24-07-01 0.11 -15.38%

Real-time Boerse Frankfurt Warrants

Last update July 05, 2024 at 03:41 pm

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying MEDTRONIC PLC
IssuerLogo Issuer Société Générale Société Générale
WKN SU2YLL
ISINDE000SU2YLL3
Date issued 2023-11-29
Strike 100 $
Maturity 2025-06-20 (350 Days)
Parity 10 : 1
Emission price 0.36
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 0.58
Lowest since issue 0.11
Delta0.17x
Omega 9.552
Premium30.6x
Gearing57.28x
Moneyness 0.7761
Difference Strike 22.39 $
Difference Strike %+22.39%
Spread 0.01
Spread %7.69%
Theoretical value 0.1250
Implied Volatility 21.97 %
Total Loss Probability 87.79 %
Intrinsic value 0.000000
Present value 0.1250
Break even 101.36 €
Theta-0x
Vega0.02x
Rho0.01x

Company Profile

Medtronic plc is one of the world leaders in designing, manufacturing and marketing of medical equipment. Net sales break down by sector of activity as follows: - general and minimally invasive surgery (28.8%): surgical equipment, intra-operative monitoring systems, ventilation systems, etc.; - cardiac rhythm management (18.6%): implantable cardiac pacemakers, implantable defibrillators and automatic external defibrillators, cardiac ablation probes, etc.; - vascular diseases and cardiac surgery (17.4%): coronary stents, endoprostheses for aortal pathologies, distal protection systems, catheters, heart valve prostheses, auto-transfusion equipment, cardiac ablation devices, etc.; - spinal disorders (14.1%): spinal prostheses, disc prostheses, cerebral stimulation systems, bone graft technologies and mini-invasive spinal surgery, etc. The group also develops medical imagery-guided surgical navigation systems activity; - neurovascular, ear, nose and throat (ENT) and pelvic diseases (8.2%); - diabetes management (7.4%): internal and external glycemia monitoring systems and insulin pumps; - neurological disorders (5.5%): neurostimulation and pumped medication administration products, diagnostic tools, etc. Net sales are distributed geographically as follows: Ireland (0.3%), the United States (50.9%) and other (48.8%).
Sector
-
More about the company

Ratings for Medtronic plc

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Consensus: Medtronic plc

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
33
Last Close Price
77.61 USD
Average target price
94.02 USD
Spread / Average Target
+21.15%
Consensus